Bellybutton Revision in Brazil
Bellybutton Revision in Brazil section, includes general infrmation about Bellybutton Revision Procedure, Bellybutton Revision Brazil Local News, Bellybutton Revision Brazil Surgeon Locator and other Bellybutton Revision related material.
Bellybutton Revision Procedure
Bellybutton Revision surgery, also known as Umbilicoplasty, is used to alter the look and shape of your bellybutton alone. The shape of your bellybutton is determined at birth, but may change over time due to weight changes, pregnancy, or an umbilical (bellybutton) hernia. Some people with minimal belly buttons or "outies" wish that they had more distinctive “innie” belly buttons, while other people dislike the shape of the navel. One may desire a "T" shape to the belly button, created by a tiny bit of overhanging abdominal skin over the top portion of the bellybutton or a horizontally shaped belly button to take on more of a vertical orientation. When a patient decides on Bell button Revision surgery as a solution to the problem, a meeting with the surgeon will determine how the belly button should look after surgery.
Bellybutton Revision surgery may be combined with other cosmetic surgery procedures, such as Liposuction, Tummy Tuck, and Breast Augmentation or done as an entirely separate procedure.
Bellybutton Revision, or Umbilicoplasty is performed with local anesthesia or conscious sedation by request of the patient. The procedure takes the average of 30 to 90 minutes. The surgery is usually performed in the doctor's office operating room, although a surgical facility may be used, especially if other procedures are performed simultaneously.
In the first 24 to 48 hours after your procedure you will notice very little swelling, bruising or discomfort. Most people return to work and normal activities either the same day or the day after the procedure. The healing process starts immediately.
The risks associated with Belly button Revision surgery are extremely rare. Though, like with all surgical procedures, there are some risks. As with any surgery, you can help reduce the risks by closely following the pre and post-surgery instructions provided to you by your surgeon. Possible risks include scarring, infections, under-correction or over-correction, or the need for further revisions. Incisions are typically hidden within the belly button and sutures are either dissolvable or removed in 7 to 10 days.
The results of Bellybutton Revision surgery are permanent except in cases of large weight gain or pregnancy after surgery.
The surgeon's fee can range from $500 to $2000. Bellybutton Revision surgery is considered cosmetic surgery, insurance does not apply.
Other Bellybutton Revision Procedures
All Body Procedures
Bellybutton Revision Brazil (current)
Brazil Buttock Augmentation
Brazil Calf Augmentation
Brazil Liposuction
Brazil Body Contouring
More Brazil info...
Brazil Regions Brazil is the fifth largest country on earth. So large is it that, for economic planning purposes, it had to be divided into five regions. The five regions (below) are drawn around state lines, but they more or less follow natural, economic and cultural borderlines.
Brazil History and Economy Until 1500, Brazil was inhabited solely by indigenous people, mainly of the Tupi and Guarani ethnic groups. Actual settling by the Portuguese began later that century, with the extraction of valuable pau-brasil wood, from which the country draws its name. The following four centuries saw further exploitation of the country's natural riches (gold and rubber) besides the rise of an economy based on agriculture (sugar and coffee) and slave labor, millions of Africans taken to the new world in a forced diaspora. Meanwhile, extermination or Christianizing of natives kept its pace, and the 19th century saw a second wave of European (mainly Italian and German) immigration, adding to this unique and complex set of factors that generated today's equally complex and unique Brazilian culture and society.
Plastic Surgery News...
- Creativity in Plastic Surgery
Content Type Journal ArticleCategory Guest EditorialDOI 10.1007/s00266-008-9137-7Authors
A. Prado, School of Medicine, Jose Joaquin Aguirre Clinical Hospital, University of Chile Plastic Surgery Division, Department of Surgery Santiago ChileP. Andrades, School of Medicine, Jose Joaquin Aguirre Clinical Hospital, University of Chile Plastic Surgery Division, Department of Surgery Santiago Chile
Journal Aesthetic Plastic SurgeryOnline ISSN 1432-5241Print ISSN 0364-216X (Source: Aesthetic Plastic Surgery)
- This review examines the evidence on rivaroxaban (Xarelto®), an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism (VTE) in patients undergoing major orthopaedic surgery of the lower limbs. A licence application was submitted to the EMEA in November 2007.
The review notes that limited data from the phase III RECORD studies (available in abstract form only) suggest that:
• Daily oral rivaroxaban 10mg is statistically significantly more effective than subcutaneous (s.c.) enoxaparin 40mg for short term thromboprophylaxis in patients undergoing total knee replacement; the primary endpoint (composite of DVT, non-fatal PE , and all-cause mortality) occurred in 9.6% and 18.9% of patients assigned to rivaroxaban or enoxaparin, respectively (p < 0.001).
• In extended thromboprophylaxis for hip arthroplasty, the same primary endpoint was achieved in 1.1% of rivaroxaban patients vs. 3.7% of those receiving enoxaparin (p < 0.001).
• Rivaroxaban and enoxaparin recipients experienced a similar incidence of major bleeding events, ranging from 0.1% to 0.6%.
No phase III liver function test data are available, but phase II data suggest that increases in liver enzymes seen in rivaroxaban recipients were of a similar order to enoxaparin recipients after 5–9 days of treatment. However caution is required until further information is available regarding safety. The review concludes “should efficacy and safety data prove favourable for oral rivoroxaban, and depending on cost, the drug might be particularly appropriate for those patients undergoing extended thromboprophylaxis after hip surgery. There will be no necessity to monitor patients for heparin-induced thrombocytopenia and a reduction in at home nurse visits may be possible. Hence, staff capacity may be released. Economic decisions concerning rivaroxaban uptake will need to balance the possible increase in drug costs versus the possible benefits that may accrue.”